Regenxbio Inc (NASDAQ:RGNX) insider Stephen Yoo sold 20,414 shares of the business’s stock in a transaction that occurred on Monday, October 29th. The shares were sold at an average price of $62.37, for a total value of $1,273,221.18. Following the completion of the sale, the insider now owns 20,414 shares of the company’s stock, valued at $1,273,221.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Stephen Yoo also recently made the following trade(s):
- On Tuesday, October 16th, Stephen Yoo sold 20,414 shares of Regenxbio stock. The shares were sold at an average price of $60.28, for a total transaction of $1,230,555.92.
Shares of RGNX opened at $70.60 on Friday. Regenxbio Inc has a one year low of $23.25 and a one year high of $85.10. The company has a market cap of $2.00 billion, a price-to-earnings ratio of -28.82, a PEG ratio of 12.43 and a beta of -1.19.
Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported $0.30 EPS for the quarter, missing the consensus estimate of $1.23 by ($0.93). Regenxbio had a net margin of 44.44% and a return on equity of 28.70%. The firm had revenue of $40.03 million for the quarter, compared to analyst estimates of $100.00 million. Equities research analysts anticipate that Regenxbio Inc will post 1.64 EPS for the current year.
Several research analysts have commented on RGNX shares. TheStreet upgraded shares of Regenxbio from a “d+” rating to a “c” rating in a research report on Monday, September 17th. Bank of America downgraded shares of Regenxbio from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $64.00 to $80.00 in a research report on Monday, July 23rd. Barclays boosted their price objective on shares of Regenxbio from $48.00 to $83.00 and gave the company an “overweight” rating in a research report on Monday, August 13th. Raymond James boosted their price objective on shares of Regenxbio from $76.00 to $96.00 and gave the company an “outperform” rating in a research report on Friday, September 7th. Finally, Chardan Capital boosted their price objective on shares of Regenxbio from $90.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, July 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $77.64.
Large investors have recently made changes to their positions in the company. Meadow Creek Investment Management LLC acquired a new position in shares of Regenxbio during the second quarter worth $141,000. Meeder Asset Management Inc. increased its holdings in shares of Regenxbio by 1,212.0% during the second quarter. Meeder Asset Management Inc. now owns 2,178 shares of the biotechnology company’s stock worth $156,000 after buying an additional 2,012 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Regenxbio during the second quarter worth $157,000. Glen Harbor Capital Management LLC acquired a new position in shares of Regenxbio during the second quarter worth $171,000. Finally, SG Americas Securities LLC acquired a new position in shares of Regenxbio during the second quarter worth $179,000. Institutional investors own 80.91% of the company’s stock.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Further Reading: What is the Dow Jones Industrial Average (DJIA)?
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.